Remove tag negotiations
article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

article thumbnail

Exploring the Earnings Landscape of Medical Sales Representatives

Rep-Lite

Importance of Understanding Medical Sales Reps Earnings Understanding the earnings landscape of medical sales jobs is crucial to career planning, negotiation, and employer competitiveness. Negotiation and Compensation Structure : Base salaries can be negotiated, and influenced by compensation structure, targets, and incentives.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Most finance-based agreements are discount schemes, including simple discounts, compulsory discounts on ex-factory prices, or other types of discount price negotiations.

Marketing 105
article thumbnail

Do healthcare mergers and acquisitions lead to better care for patients?

Clarify Health

Better negotiating power : With increased focus on price transparency and lowering healthcare costs, healthcare mergers and acquisitions mean that smaller systems can lean into the increased bargaining power of larger organizations. The diminished market competition resulting from mergers is at the forefront of those concerns.

Leads 52
article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP. CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression.

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

However, with a price tag of €1.58 The difficulty in negotiating the area is that both sides are arriving from opposing standpoints: the industry will charge what it believes the market can bear, while the countries want to pay a price that leaves sufficient budget to reimburse other treatments and solutions. At more than $2.1

Medicine 118
article thumbnail

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

PM360

The accumulation of the right data—including safety, efficacy, and outcomes—are vital to negotiations with payers as opposed to what regulators are looking for. This option grows more critical as new therapies become available with price tags as high as $3.5 million for the new hemophilia gene therapy. References: 1.